Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Heal Clinics is a health and wellness service provider offerring the HEALcare keto...
Heal Clinics is a health and wellness service p...
Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suff...
Marinus Pharmaceuticals, Inc. is committed to i...
Ansell Limited provides health and safety protection solutions. The Company has op...
Ansell Limited provides health and safety prote...
As a leading genome editing company, Editas Medicine is focused on translating the...
As a leading genome editing company, Editas Med...
Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company, and a leading ...
Founded in 1941 in Tokyo, Japan, Hoya is a glob...
STRATA Skin Sciences is a medical technology company focused on the therapeutic an...
STRATA Skin Sciences is a medical technology co...
Alkermes plc is a fully integrated, global biopharmaceutical company developing in...
Alkermes plc is a fully integrated, global biop...
Join the National Investor Network and get the latest information with your interests in mind.